Review of clinical studies of perampanel in adolescent patients

Heung Dong Kim, Ching Shiang Chi, Tayard Desudchit, Marina Nikanorova, Anannit Visudtibhan, Charcrin Nabangchang, Derrick W S Chan, Choong Yi Fong, Kai Ping Chang, Shang Yeong Kwan, Fe De Los Reyes, Chao Ching Huang, Surachai Likasitwattanakul, Wang Tso Lee, Ada Yung, Amitabh Dash

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Aim: To assess the clinical trial and real-world data for adjunctive perampanel in adolescents and develop consensus recommendations to guide the use of perampanel in this population in clinical practice. Methods: In May 2015, 15 epilepsy experts attended a Consensus Development Meeting to assess the clinical trial data for perampanel, specific to the adolescent age group (12-17 years) and develop consensus treatment recommendations. Results and Discussion: Analysis of the adolescent subgroup data of three pivotal placebo-controlled, double-blind, phase 3 trials investigating perampanel in patients with ongoing focal epileptic seizures despite receiving one to three antiepileptic drugs found that perampanel 4–12 mg was superior to placebo. The tolerability profile of perampanel was generally acceptable. Adolescent patients receiving long-term treatment with perampanel in an open-label extension study maintained improvements in seizure control compared with baseline, with a favorable risk-benefit profile. A phase 2 study showed that perampanel had no clinically important effects on cognitive function, growth, and development. Conclusion: Perampanel is a welcome addition to the armamentarium of existing antiepileptic drugs as it represents a new approach in the management of epilepsy, with a novel mechanism of action, and the potential to have a considerable impact on the treatment of adolescents with epilepsy.

Original languageEnglish
Article numbere00505
JournalBrain and Behavior
Volume6
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Epilepsy
Consensus
Anticonvulsants
Seizures
Pragmatic Clinical Trials
Placebos
Clinical Studies
perampanel
Growth and Development
Cognition
Action Potentials
Therapeutics
Age Groups
Clinical Trials
Population

Keywords

  • Adolescent
  • Anticonvulsants
  • consensus
  • epilepsy
  • perampanel
  • receptors AMPA

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Kim, H. D., Chi, C. S., Desudchit, T., Nikanorova, M., Visudtibhan, A., Nabangchang, C., ... Dash, A. (2016). Review of clinical studies of perampanel in adolescent patients. Brain and Behavior, 6(9), [e00505]. https://doi.org/10.1002/brb3.505

Review of clinical studies of perampanel in adolescent patients. / Kim, Heung Dong; Chi, Ching Shiang; Desudchit, Tayard; Nikanorova, Marina; Visudtibhan, Anannit; Nabangchang, Charcrin; Chan, Derrick W S; Fong, Choong Yi; Chang, Kai Ping; Kwan, Shang Yeong; Reyes, Fe De Los; Huang, Chao Ching; Likasitwattanakul, Surachai; Lee, Wang Tso; Yung, Ada; Dash, Amitabh.

In: Brain and Behavior, Vol. 6, No. 9, e00505, 01.09.2016.

Research output: Contribution to journalReview article

Kim, HD, Chi, CS, Desudchit, T, Nikanorova, M, Visudtibhan, A, Nabangchang, C, Chan, DWS, Fong, CY, Chang, KP, Kwan, SY, Reyes, FDL, Huang, CC, Likasitwattanakul, S, Lee, WT, Yung, A & Dash, A 2016, 'Review of clinical studies of perampanel in adolescent patients', Brain and Behavior, vol. 6, no. 9, e00505. https://doi.org/10.1002/brb3.505
Kim HD, Chi CS, Desudchit T, Nikanorova M, Visudtibhan A, Nabangchang C et al. Review of clinical studies of perampanel in adolescent patients. Brain and Behavior. 2016 Sep 1;6(9). e00505. https://doi.org/10.1002/brb3.505
Kim, Heung Dong ; Chi, Ching Shiang ; Desudchit, Tayard ; Nikanorova, Marina ; Visudtibhan, Anannit ; Nabangchang, Charcrin ; Chan, Derrick W S ; Fong, Choong Yi ; Chang, Kai Ping ; Kwan, Shang Yeong ; Reyes, Fe De Los ; Huang, Chao Ching ; Likasitwattanakul, Surachai ; Lee, Wang Tso ; Yung, Ada ; Dash, Amitabh. / Review of clinical studies of perampanel in adolescent patients. In: Brain and Behavior. 2016 ; Vol. 6, No. 9.
@article{5d5cbd6a994947f8b7792af0be8e9258,
title = "Review of clinical studies of perampanel in adolescent patients",
abstract = "Aim: To assess the clinical trial and real-world data for adjunctive perampanel in adolescents and develop consensus recommendations to guide the use of perampanel in this population in clinical practice. Methods: In May 2015, 15 epilepsy experts attended a Consensus Development Meeting to assess the clinical trial data for perampanel, specific to the adolescent age group (12-17 years) and develop consensus treatment recommendations. Results and Discussion: Analysis of the adolescent subgroup data of three pivotal placebo-controlled, double-blind, phase 3 trials investigating perampanel in patients with ongoing focal epileptic seizures despite receiving one to three antiepileptic drugs found that perampanel 4–12 mg was superior to placebo. The tolerability profile of perampanel was generally acceptable. Adolescent patients receiving long-term treatment with perampanel in an open-label extension study maintained improvements in seizure control compared with baseline, with a favorable risk-benefit profile. A phase 2 study showed that perampanel had no clinically important effects on cognitive function, growth, and development. Conclusion: Perampanel is a welcome addition to the armamentarium of existing antiepileptic drugs as it represents a new approach in the management of epilepsy, with a novel mechanism of action, and the potential to have a considerable impact on the treatment of adolescents with epilepsy.",
keywords = "Adolescent, Anticonvulsants, consensus, epilepsy, perampanel, receptors AMPA",
author = "Kim, {Heung Dong} and Chi, {Ching Shiang} and Tayard Desudchit and Marina Nikanorova and Anannit Visudtibhan and Charcrin Nabangchang and Chan, {Derrick W S} and Fong, {Choong Yi} and Chang, {Kai Ping} and Kwan, {Shang Yeong} and Reyes, {Fe De Los} and Huang, {Chao Ching} and Surachai Likasitwattanakul and Lee, {Wang Tso} and Ada Yung and Amitabh Dash",
year = "2016",
month = "9",
day = "1",
doi = "10.1002/brb3.505",
language = "English",
volume = "6",
journal = "Brain and Behavior",
issn = "2157-9032",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Review of clinical studies of perampanel in adolescent patients

AU - Kim, Heung Dong

AU - Chi, Ching Shiang

AU - Desudchit, Tayard

AU - Nikanorova, Marina

AU - Visudtibhan, Anannit

AU - Nabangchang, Charcrin

AU - Chan, Derrick W S

AU - Fong, Choong Yi

AU - Chang, Kai Ping

AU - Kwan, Shang Yeong

AU - Reyes, Fe De Los

AU - Huang, Chao Ching

AU - Likasitwattanakul, Surachai

AU - Lee, Wang Tso

AU - Yung, Ada

AU - Dash, Amitabh

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Aim: To assess the clinical trial and real-world data for adjunctive perampanel in adolescents and develop consensus recommendations to guide the use of perampanel in this population in clinical practice. Methods: In May 2015, 15 epilepsy experts attended a Consensus Development Meeting to assess the clinical trial data for perampanel, specific to the adolescent age group (12-17 years) and develop consensus treatment recommendations. Results and Discussion: Analysis of the adolescent subgroup data of three pivotal placebo-controlled, double-blind, phase 3 trials investigating perampanel in patients with ongoing focal epileptic seizures despite receiving one to three antiepileptic drugs found that perampanel 4–12 mg was superior to placebo. The tolerability profile of perampanel was generally acceptable. Adolescent patients receiving long-term treatment with perampanel in an open-label extension study maintained improvements in seizure control compared with baseline, with a favorable risk-benefit profile. A phase 2 study showed that perampanel had no clinically important effects on cognitive function, growth, and development. Conclusion: Perampanel is a welcome addition to the armamentarium of existing antiepileptic drugs as it represents a new approach in the management of epilepsy, with a novel mechanism of action, and the potential to have a considerable impact on the treatment of adolescents with epilepsy.

AB - Aim: To assess the clinical trial and real-world data for adjunctive perampanel in adolescents and develop consensus recommendations to guide the use of perampanel in this population in clinical practice. Methods: In May 2015, 15 epilepsy experts attended a Consensus Development Meeting to assess the clinical trial data for perampanel, specific to the adolescent age group (12-17 years) and develop consensus treatment recommendations. Results and Discussion: Analysis of the adolescent subgroup data of three pivotal placebo-controlled, double-blind, phase 3 trials investigating perampanel in patients with ongoing focal epileptic seizures despite receiving one to three antiepileptic drugs found that perampanel 4–12 mg was superior to placebo. The tolerability profile of perampanel was generally acceptable. Adolescent patients receiving long-term treatment with perampanel in an open-label extension study maintained improvements in seizure control compared with baseline, with a favorable risk-benefit profile. A phase 2 study showed that perampanel had no clinically important effects on cognitive function, growth, and development. Conclusion: Perampanel is a welcome addition to the armamentarium of existing antiepileptic drugs as it represents a new approach in the management of epilepsy, with a novel mechanism of action, and the potential to have a considerable impact on the treatment of adolescents with epilepsy.

KW - Adolescent

KW - Anticonvulsants

KW - consensus

KW - epilepsy

KW - perampanel

KW - receptors AMPA

UR - http://www.scopus.com/inward/record.url?scp=84977588018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977588018&partnerID=8YFLogxK

U2 - 10.1002/brb3.505

DO - 10.1002/brb3.505

M3 - Review article

AN - SCOPUS:84977588018

VL - 6

JO - Brain and Behavior

JF - Brain and Behavior

SN - 2157-9032

IS - 9

M1 - e00505

ER -